Measuring arsenic exposure, metabolism, and biological effects: The role of urine proteomics

Toxicological Sciences

Volumn 106, Issue 1, 2008, Pages 1-4

  Navas Acien, Ana ^a,b   Guallar, Eliseo ^b,c,d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

Arsenic; Biomarkers; Defensins; Proteomics; Urine

Indexed keywords

ARSENIC; BETA DEFENSIN 1; BIOLOGICAL MARKER; DRINKING WATER;

ARSENIC POISONING; ARTICLE; CHEMICAL CARCINOGENESIS; ENVIRONMENTAL EXPOSURE; HEALTH HAZARD; HUMAN; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; URINALYSIS; WATER CONTAMINATION; XENOBIOTIC METABOLISM;

ARSENIC; BETA-DEFENSINS; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENVIRONMENTAL MONITORING; HUMANS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; WATER POLLUTANTS, CHEMICAL;

EID: 54349083844     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfn172     Document Type: Article

References (30)

1. Andrew, A. S., Burgess, J. L., Meza, M. M., Demidenko, E., Waugh, M. G., Hamilton, J. W., and Karagas, M. R. (2006). Arsenic exposure is associated with decreased DNA repair in vitro and in individuals exposed to drinking water arsenic. Environ. Health Perspect. 114, 1193-1198.
2. Andrew, A. S., Jewell, D. A., Mason, R. A., Whitfield, M. L., Moore, J. H., and Karagas, M. R. (2008). Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ. Health Perspect. 116, 524-531.
3. Aposhian, H. V., and Aposhian, M. M. (2006). Arsenic toxicology: Five questions. Chem. Res. Toxicol. 19, 1-15.
4. Benbrahim-Tallaa, L., and Waalkes, M. P. (2008). Inorganic arsenic and human prostate cancer. Environ. Health Perspect. 116, 158-164.
5. Braman, R. S., and Foreback, C. C. (1973). Methylated forms of arsenic in environment. Science 182, 1247-1249.
6. Chen, C. J., Hsu, L. I., Wang, C. H., Shih, W. L., Hsu, Y. H., Tseng, M. P., Lin, Y. C., Chou, W. L., Chen, C. Y., Lee, C. Y., et al. (2005). Biomarkers of exposure, effect, and susceptibility of arsenic-induced health hazards in Taiwan. Toxicol. Appl. Pharmacol. 206, 198-206.
7. Donald, C. D., Sun, C. Q., Lim, S. D., Macoska, J., Cohen, C., Amin, M. B., Young, A. N., Ganz, T. A., Marshall, F. F., and Petros, J. A. (2003). Cancer-specific loss of beta-defensin 1 in renal and prostatic carcinomas. Lab. Invest. 83, 501-505.
8. Francesconi, K. A., and Kuehnelt, D. (2004). Determination of arsenic species: A critical review of methods and applications, 2000-2003. Analyst 129, 373-395.
9. Ganz, T. (2003). Defensins: Antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3, 710-720.
10. Harezlak, J., Wu, M. C., Wang, M., Schwartzman, A., Christiani, D. C., and Lin, X. (2008). Biomarker discovery for arsenic exposure using functional data. Analysis and feature learning of mass spectrometry proteomic data. J. Proteome Res. 7, 217-224.
11. Hegedus, C. M., Skibola, C. F., Warner, M., Skibola, D. R., Alexander, D., Lim, S., Dangleben, N., Zhang, L., Clark, M., Pfeiffer, R. M., et al. (2008). Decreased urinary beta defensin-1 expression as a biomarker of response to arsenic. Toxicol. Sci. Advance Access published on May 28, 2008. doi: 10.1093/toxsci/kfn104.
12. Holterman, D. A., Diaz, J. I., Blackmore, P. F., Davis, J.W., Schellhammer, P. F., Corica, A., Semmes, O. J., and Vlahou, A. (2006). Overexpression of alpha-defensin is associated with bladder cancer invasiveness. Urol. Oncol. 24, 97-108.
13. Hughes, M. F. (2006). Biomarkers of exposure: A case study with inorganic arsenic. Environ. Health Perspect. 114, 1790-1796.
14. International Agency for Research on Cancer. (2002). Some drinking water disinfectants and contaminants, including arsenic. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, IARC, Lyon.
15. Kougias, P., Chai, H., Lin, P. H., Yao, Q., Lumsden, A. B., and Chen, C. (2005). Defensins and cathelicidins: Neutrophil peptides with roles in inflammation, hyperlipidemia and atherosclerosis. J. Cell. Mol. Med. 9, 3-10.
16. Meliker, J. R., Wahl, R. L., Cameron, L. L., and Nriagu, J. O. (2007). Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: A standardized mortality ratio analysis. Environ. Health 6, 4.
17. National Research Council. (1999). Arsenic in drinking water. National Academy Press, Washington, DC.
18. Navas-Acien, A., Sharrett, A. R., Silbergeld, E. K., Schwartz, B. S., Nachman, K. E., Burke, T. A., and Guallar, E. (2005). Arsenic exposure and cardiovascular disease: A systematic review of the epidemiologic evidence. Am. J. Epidemiol. 162, 1037-1049.
19. Navas-Acien, A., Silbergeld, E. K., Pastor-Barriuso, R., and Guallar, E. (2008). Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA 300, 814-822.
20. Navas-Acien, A., Silbergeld, E. K., Streeter, R. A., Clark, J. M., Burke, T. A., and Guallar, E. (2006). Arsenic exposure and type 2 diabetes: A systematic review of the experimental and epidemiological evidence. Environ. Health Perspect. 114, 641-648.
21. Pazgier, M., Hoover, D. M., Yang, D., Lu, W., and Lubkowski, J. (2006). Human beta-defensins. Cell Mol. Life Sci. 63, 1294-1313.
22. Simeonova, P. P., and Luster, M. I. (2000). Mechanisms of arsenic carcinogenicity: Genetic or epigenetic mechanisms? J. Environ. Pathol. Toxicol. Oncol. 19, 281-286.
23. Smedley, P. L., and Kinniburgh, D. G. (2002). A review of the source, behaviour and distribution of arsenic in natural waters. Appl. Geochem. 17, 517-568.
24. Soucy, N. V., Ihnat, M. A., Kamat, C. D., Hess, L., Post, M. J., Klei, L. R., Clark, C., and Barchowsky, A. (2003). Arsenic stimulates angiogenesis and tumorigenesis in vivo. Toxicol. Sci. 76, 271-279.
25. Sun, C. Q., Arnold, R., Fernandez-Golarz, C., Parrish, A. B., Almekinder, T., He, J., Ho, S. M., Svoboda, P., Pohl, J., Marshall, F. F., et al. (2006). Human beta-defensin-1, a potential chromosome 8p tumor suppressor: Control of transcription and induction of apoptosis in renal cell carcinoma. Cancer Res. 66, 8542-8549.
26. Tan, B. L., Chen, K. T., Tyan, Y. C., Liao, P. C., and Guo, H. R. (2008). Proteomic analysis for human urinary proteins associated with arsenic intoxication. Proteomics Clin. Appl. 2, 1087-1098.
27. Valore, E. V., Park, C. H., Quayle, A. J., Wiles, K. R., McCray, P. B., Jr., and Ganz, T. (1998). Human beta-defensin-1: An antimicrobial peptide of urogenital tissues. J. Clin. Invest. 101, 1633-1642.
28. Vlahou, A., Schellhammer, P. F., Mendrinos, S., Patel, K., Kondylis, F. I., Gong, L., Nasim, S., and Wright, J. G., Jr. (2001). Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 158, 1491-1502.
29. Young, A. N., de Oliveira Salles, P. G., Lim, S. D., Cohen, C., Petros, J. A., Marshall, F. F., Neish, A. S., and Amin, M. B. (2003). Beta defensin-1, parvalbumin, and vimentin: A panel of diagnostic immunohistochemical markers for renal tumors derived from gene expression profiling studies using cDNA microarrays. Am. J. Surg. Pathol. 27, 199-205.
30. Zhai, R., Su, S., Lu, X., Liao, R., Ge, X., He, M., Huang, Y., Mai, S., Lu, X., and Christiani, D. (2005). Proteomic profiling in the sera of workers occupationally exposed to arsenic and lead: Identification of potential biomarkers. Biometals 18, 603-613.